Results 41 to 50 of about 1,047 (134)

Case Report: Paraneoplastic Tumefactive Demyelination Associated With Seminoma

Frontiers in Neurology, 2022
Paraneoplastic tumefactive demyelination (TD) is a rare disorder of the central nervous system that can be challenging to diagnose. Here, we describe a 32-year-old Japanese man with a TD associated with testicular seminoma.
Wataru Shiraishi, Wataru Shiraishi, Takeru Umemura, Yuuki Nakayama, Yui Yamada, Masahiro Shijo, Masahiro Shijo, Tetsuya Hashimoto   +7 more
doaj   +1 more source

Demyelinating Pseudotumours Presenting as Space Occupying Lesions Mimicking Brain Tumours- A Histopathologic Assessment of Seven Cases [PDF]

Journal of Clinical and Diagnostic Research, 2020
Demyelinating lesions which present as solitary contrast-enhancing masses pose a diagnostic challenge for both radiologists and surgical neuropathologists and can mimic a number of intracranial space occupying lesions either neoplastic/inflammatory ...
B DEEPTHI, SOMASEKHAR POTHULA
doaj   +1 more source

MR imaging findings in primary spinal cord glioblastoma

Radiology Case Reports, 2021
Spinal cord glioblastoma is a rare disease, with an aggressive course and a poor prognosis. We describe magnetic resonance imaging (MRI) findings, in 3 adult cases of biopsy-confirmed glioblastoma.Conventional MRI findings were unclear with regard to the
Paolo Ferrante, MD, Juan Andres Mora, MD, Lourdes Salazar, MD, Elena Martínez Sáez, MD, Cristina Auger, MD, Àlex Rovira, MD   +5 more
doaj   +1 more source

Tumefactive multiple sclerosis: the lethal chameleon

European Journal of Case Reports in Internal Medicine
Tumefactive multiple sclerosis (TMS) is a rare variant of multiple sclerosis that presents with a large demyelinating lesion in the central nervous system, accompanied by peripheral ring-like enhancement, perilesional oedema and mass effect.
Ana Carolina Monteiro, Tomás França de Santana, Carolina Chumbo, Catarina Negrão, Teresa Valido, Filipa Figueiredo, Clara Matos   +6 more
doaj   +1 more source

Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments [PDF]

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Objective Large demyelinating lesions with possible mass effect (tumefactive multiple sclerosis or tumefactive demyelination) can be mistaken for tumour-like space-occupying lesions suggesting a malignant outcome. Methods We reviewed our own experience of multiple sclerosis subjects ( n = 28) with tumefactive demyelination to determine the relationship
Staley A Brod, J William Lindsey, Flavia Nelson   +2 more
openaire   +2 more sources

Tumefactive Demyelinating Lesions and Pregnancy

Neurology India, 2019
Until now, only one gestational tumefactive demyelinating lesion (TDL) has been described. Here we report two TDL cases occurring during and after the pregnancy. A 26-year-old 6-week pregnant woman developed a 3-cm left frontotemporoparietal subcortical TDL with inhomogeneous partial enhancement.
Plantone, Domenico, Piantadosi, Carlo, Ruggieri, Serena, Anelli, Vincenzo, Koudriavtseva, Tatiana   +4 more
openaire   +3 more sources

Quantitative Assessment of Upper Limb Ataxia Using a Virtual Reality‐Based Evaluation System

Annals of Clinical and Translational Neurology, Volume 13, Issue 1, Page 180-192, January 2026.
ABSTRACT Objective Cerebellar ataxia impairs coordination and balance, reducing quality of life. Conventional clinical scales, including the Scale for the Assessment and Rating of Ataxia (SARA) and the International Cooperative Ataxia Rating Scale (ICARS), are widely used to assess ataxia but are limited by subjectivity and inter‐rater variability ...
Masayuki Sato, Takayuki Abe, Sho Aoki, Setsuki Tsukagoshi, Yasushi Yuminaka, Yoshio Ikeda   +5 more
wiley   +1 more source

Double Anti‐NMO and Anti‐MOG Positivity in a Patient With Metastatic Renal Carcinoma: First Reported Case

Case Reports in Neurological Medicine, Volume 2026, Issue 1, 2026.
Background Neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein‐associated disease (MOGAD) are central nervous system (CNS) demyelinating disorders characterized by autoantibodies targeting aquaporin‐4 (AQP4) and MOG, respectively.
M. Fortanet García, A. Belenguer Benavides, S. Blanco Madera, H. Benetó Andrés, A. Monclus Beclua, A. Recio Gimeno, L. Popova, Isabella Laura Simone   +7 more
wiley   +1 more source

MOG antibody associated disease (MOGAD) presenting with extensive brain stem encephalitis: A case report

eNeurologicalSci, 2022
Background: Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) is a relatively new entity of demyelinating diseases, clinically presenting with optic neuritis, transverse myelitis, or encephalic symptoms.
Elisabeth Olbert, Cornelia Brunner, Naela Alhani, Christian Našel, Walter Struhal   +4 more
doaj   +1 more source

Neuro-oncology dilemma: Tumour or tumefactive demyelinating lesion [PDF]

Multiple Sclerosis and Related Disorders, 2015
Tumefactive demyelinating lesions (TDLs) are not an uncommon manifestation of demyelinating disease but can pose diagnostic challenges in patients without a pre-existing diagnosis of multiple sclerosis (MS) as well as in known MS patients. Brain tumours can also arise in MS patients and can be seen in chronic MS patients as co-morbidities.
Mohammad, Abdoli, Mark S, Freedman
openaire   +2 more sources